Recent Updates
Recently added Catalysts

Lyra Therapeutics, Inc.

LYRA
Richly ValuedBiotech · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$0.28
▼ -0.13 · -14.77%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full LYRA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.4852W HIGH $37.50
Volume
11.26 K
Value Traded
3.17 K
Short % Float
0.37%
-61.63%Week
-63.33%1 Month
-87.4%3 Month
-92.24%6 Month
-99.93%5 Year
-99.95%All Time

Cash Data

Unlock LYRA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
878.57 K
EPS (TTM)
-23.78
P/E Ratio
-
Ent. Value
10.20 M
Total Shares
1.64 M
Float Shares
1.34 M
Insiders
7.93%
Institutions
13.67%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every LYRA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

LYRA Catalyst Timeline

Dated clinical, regulatory and corporate events for Lyra Therapeutics, Inc.

Unlock the full LYRA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How LYRA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-10-01LYR-210 (mometasone furoate) Phase 3 data presentation Phase 3
Unlock all LYRA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

F15 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Lyra Therapeutics, Inc. has significant pipeline risk (15/100), with $45M risk-adjusted pipeline value, led by LYR-220 Design 1 in Chronic Sinusitis (Phase 2), but cash runway is a concern.
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
LYR-220 Design 1 Small moleculeCompletedNCT05035654Chronic SinusitisPhase 2 COMPLETED 48Aug 30, 2023
Unlock the LYRA pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every LYRA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
LYR-210 chronic rhinosinusitis without nasal polypsPhase 32025-10-06LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24; symptom improvement observed as early as week 4Read MoreLyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 StudyRead More
Scroll for more · summaries link to the source press release
Unlock every LYRA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock LYRA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Palasis MariaDirector, Officer (Principal Executive Officer)Disposition -2,000 1,094,733 held$0.00 04/01/2026
Unlock the full LYRA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in LYRA

Fund % of Portfolio Current MV Shares Owned Activity
Ikarian Capital, LLC 0 % 65.00 K 21.16 K
Unlock every fund holding LYRA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in LYRA
Shares held by hedge funds each quarter, and who bought or sold.

LYRA Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock LYRA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live LYRA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock LYRA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How LYRA ranks across every disease it competes in

Competitive Position is a premium feature
See how LYRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

LYRA News

About Lyra Therapeutics, Inc.

87 employees lyratherapeutics.com
HeadquartersWatertown
Founded2005
BIOPHARMAWATCH ELITE PLUS
Trade the next LYRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime